A detailed history of Johnson Financial Group, Inc. transactions in Novo Nordisk A S stock. As of the latest transaction made, Johnson Financial Group, Inc. holds 371 shares of NVO stock, worth $39,088. This represents 0.0% of its overall portfolio holdings.

Number of Shares
371
Previous 662 43.96%
Holding current value
$39,088
Previous $85,000 38.82%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$122.71 - $146.91 $35,708 - $42,750
-291 Reduced 43.96%
371 $52,000
Q1 2024

May 14, 2024

BUY
$102.11 - $135.92 $16,337 - $21,747
160 Added 31.87%
662 $85,000
Q4 2023

Feb 09, 2024

BUY
$87.78 - $105.45 $5,969 - $7,170
68 Added 15.67%
502 $51,000
Q3 2023

Nov 14, 2023

BUY
$90.94 - $199.54 $19,733 - $43,300
217 Added 100.0%
434 $39,000
Q2 2023

Aug 14, 2023

SELL
$155.98 - $172.65 $5,615 - $6,215
-36 Reduced 14.23%
217 $35,000
Q1 2023

May 12, 2023

BUY
$132.34 - $159.14 $33,482 - $40,262
253 New
253 $40,000
Q1 2020

May 14, 2020

SELL
$49.46 - $64.78 $19,042 - $24,940
-385 Closed
0 $0
Q4 2019

Feb 14, 2020

SELL
$49.86 - $58.26 $1,096 - $1,281
-22 Reduced 5.41%
385 $22,000
Q3 2019

Nov 12, 2019

BUY
$47.54 - $53.43 $6,798 - $7,640
143 Added 54.17%
407 $21,000
Q1 2019

May 13, 2019

SELL
$46.36 - $52.63 $7,649 - $8,683
-165 Reduced 38.46%
264 $14,000
Q4 2018

Feb 11, 2019

SELL
$41.54 - $47.25 $3,073 - $3,496
-74 Reduced 14.71%
429 $20,000
Q3 2018

Nov 09, 2018

BUY
$46.76 - $51.24 $3,460 - $3,791
74 Added 17.25%
503 $24,000
Q3 2017

Nov 09, 2017

BUY
$41.15 - $49.22 $17,653 - $21,115
429
429 $21,000

Others Institutions Holding NVO

About NOVO NORDISK A S


  • Ticker NVO
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 2,257,289,984
  • Market Cap $238B
  • Description
  • Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabeti...
More about NVO
Track This Portfolio

Track Johnson Financial Group, Inc. Portfolio

Follow Johnson Financial Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Johnson Financial Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Johnson Financial Group, Inc. with notifications on news.